Psychiatry finally has new drugs, now they must prove it. After decades of drugs that work the same way, new ones are here: medicines that act within days, not weeks, and schizophrenia drugs built on a different target. The catch is proving they work in trials where placebo often looks good too. This report covers the whole market, from depression and schizophrenia to ADHD and addiction.
12 sections to help founders and investors understand the neuropsychiatric therapeutics market with clarity
Psychiatric drugs often get lumped in with therapy apps, brain devices and neurology, so we begin by marking the edges.
A pill for schizophrenia, a nasal spray for depression or a psilocybin treatment still in trials is in. A meditation app, a talk therapy service or a drug for Parkinson's with no psychiatric use is out.
That way, every number and every company in the report belongs to the same market.
Psychiatry drugs are back on big pharma's shopping list, even after a long run of failed trials.
We've found a lot of interesting signals. For example, in April 2026, the FDA gave Compass Pathways' psilocybin treatment for treatment-resistant depression a national priority voucher, which can shorten the review once the full application is in. Then in September, Eli Lilly closed its purchase of AtaiBeckley, in a deal worth up to $3.8B built around a fast-acting psychedelic drug for the same condition. Regulators are opening a quicker path for a new kind of depression treatment, and big drugmakers are paying to be there early.
In this section, we look at why money is returning to psychiatry now, which conditions and mechanisms buyers want most, and what this means for smaller drug developers.
Market sizes for psychiatric drugs online often mix in old generics, therapy services and neurology drugs, so the figures rarely match.
We use first principles. We build our own estimate from patients, treatments and prices, check it against other sources, and explain each assumption along the way.
We also show how the number changes in a cautious and an optimistic scenario, since a few approvals or failures can move this market a lot.
Hundreds of millions of people live with depression, anxiety or schizophrenia, and many of them don't get better on the drugs they're given.
We compare six types of companies, from big pharma with psychiatry brands to developers of fast-acting depression drugs, psychedelics, new schizophrenia mechanisms and long-acting injections. Then we rank what patients, doctors and payers need most: drugs that work faster, fewer side effects like weight gain or sedation, and treatments people keep taking.
This shows which problems are worth a new drug, and why matching an old generic on effect is rarely enough.
For years, most psychiatric drugs worked on the same few brain chemicals. Newer ones try other targets, like muscarinic receptors in schizophrenia or rapid changes in brain wiring in depression.
We map the approaches one by one, from classic pills and long-acting injections to nasal sprays and psychedelic treatments given in a clinic. We also show where things get stuck, like high placebo response in trials, patients who drop out, and treatments that need hours of supervision.
You'll see which drugs are already sold, which are in late trials, and which are still early.
Psychiatric drug companies make money through prescriptions paid by insurers and public programs, long-acting shots given in clinics, treatments delivered in certified centers, and licensing or selling their drugs to bigger partners.
We compare who pays, and what each type of treatment costs to deliver. Public programs like Medicaid pay for a large share of schizophrenia care and push hard on price. A long-acting shot can earn more per patient because people stay on it longer. A treatment given in a clinic also needs a room, a trained team and someone to pay for the hours. And a small developer that sells early gets cash, but gives up the launch.
You'll see which models still make money once generics, rebates and clinic costs are counted.
Some brakes are easy to see: trials that fail because placebo works too well, side effects that make patients quit, and cheap generics that set a low bar on price.
Others are easier to miss. Psychedelic drugs still need drug rules to change before they can be sold. Clinics may not have the space or staff to supervise long sessions. Insurers can ask patients to fail older drugs first. And a safety problem with one new drug could make doctors wary of the whole class.
We go through these risks one by one, rate how likely each is, and show who would feel it first.
Growth here depends on a few forces that have to keep working. We take them one at a time.
Some drivers are plain to see: a large number of patients who don't respond to current drugs, new mechanisms reaching late trials, and more attention to mental health. Others build on each other. Each approval of a new kind of drug makes the next trial easier to fund. More clinics set up for supervised treatments make it easier to launch the next one. And when big pharma buys a developer, investors become more willing to back others.
Before building or investing, you should know what makes doctors prescribe a new psychiatric drug, and what keeps patients taking it.
Psychiatry was out of favor with investors for years. Now big drugmakers are paying again, and venture funds are following.
We compare recent rounds and deals across fast-acting depression drugs, psychedelics, new schizophrenia mechanisms and long-acting treatments. We'll also look at how much buyers pay for a drug before or after phase 3, and which newer bets, like non-psychedelic versions of these drugs, are starting to get funded.
You'll see where psychiatry money is going after deals like Lilly's purchase of AtaiBeckley, and what results a smaller developer needs before it can raise today.
Johnson & Johnson, with Spravato, and Bristol Myers Squibb, with Cobenfy, get most of the attention in psychiatric drugs, but they're far from the whole field.
Many of the most interesting players work on narrow problems. Some develop drugs for postpartum depression or PTSD. Others are trying to make psychedelic treatments shorter so they fit a normal clinic visit, or developing new drugs for addiction and ADHD that don't work like stimulants.
They're hard to compare because psychiatric trials use rating scales, patient groups and timelines that differ from one study to the next. A strong early result often shrinks in a bigger trial, so a single headline number says little.
Below, you'll find the market grids and ecosystem maps we've built to show who works on which condition and mechanism, and where new players are getting in.
In psychiatry, a drug can fail even when patients feel better. If the placebo group feels better too, the trial is lost.
So we studied why psychiatric drug startups fail or stall. Some move into large trials after a small study that looked great. Others build a treatment that works but needs hours of supervision nobody has planned to pay for. And some depend on a single drug, so one failed trial ends the company.
If you're building, you'll see why trial design, patient selection and a clear plan for how the drug will be given matter as much as the science. If you're investing, you'll know what to check about placebo response, cash for a second trial and how much depends on one program.
Karuna Therapeutics, Intra-Cellular Therapies, Axsome Therapeutics… a few psychiatry drug makers have turned one new medicine into a real outcome.
Karuna Therapeutics took a new kind of schizophrenia drug through late trials, and Bristol Myers Squibb paid $14B for it before approval. Intra-Cellular Therapies built Caplyta into a growing brand, then sold to Johnson & Johnson for $14.6B. Axsome Therapeutics chose to launch Auvelity for depression on its own. Two sold, one stayed independent, and each path came with its own trade-offs.
We'll look at how these teams picked a condition where patients needed something different, ran trials that held up, and decided whether to sell or launch the drug themselves.
It's for founders, investors, pharma and biotech teams, payers, clinic operators and strategists who want a clear view of neuropsychiatric drugs.
Use it to compare depression, schizophrenia, ADHD and addiction programs, to judge new mechanisms against cheap generics, to plan for treatments given in a clinic, to decide between partnering and launching alone, or to understand demand, technology, funding, competitors and risks across the whole market.
It has 190+ pages. It is designed to be comprehensive enough to support serious market evaluation, while still being fast to read and easy to use.
We prioritize signal, structure, and visual clarity over unnecessary length.
We define the neuropsychiatric therapeutics market as medicines developed to treat psychiatric conditions and related brain disorders.
We include drug programs for depression, schizophrenia, anxiety and other neuropsychiatric indications, such as bipolar disorder, PTSD, ADHD and substance use disorders.
We exclude psychotherapy services, wellness apps and neurological treatments without a psychiatric or behavioral indication.
Yes. All key data points and assumptions are explained and sourced in the document.
All sources are tier-1: company filings, funding databases, public datasets, expert interviews, industry reports, etc.
Yes. The report was last updated on November 8, 2026 with the latest market signals.
Yes. This is a one-time purchase. There is no subscription required to access the document.
Yes. You can use NEWMARKET for 20% off when purchasing two reports, or NEWMARKETMAX for 30% off when purchasing five or more.
If a market you care about is not currently on the list, email us at team@newmarketpitch.com and we may be able to cover it.
No problem. You can reach out directly and we respond within 24 hours.
Most psychiatric drugs are cheap generics, so a new one has to be clearly better to win a place. This report covers the whole neuropsychiatric therapeutics market, from size and patients to science, pricing, funding, competitors, risks and the openings that remain.
